患者登録ソフトウェア市場 – 2030年までの世界予測

本レポートは、患者レジストリソフトウェア市場を分析しています。製品、レジストリの種類、ユースケース、導入モデル、エンドユーザー、地域別に分類し、様々なセグメントの市場規模と将来の成長ポテンシャルを予測することを目的としています。さらに、本レポートには、この市場における主要プレーヤーの競合分析が含まれており、企業概要、製品ラインナップ、最近の動向、主要な市場戦略などを取り上げています。

The global patient registry software market is expected to reach USD 3.61 billion by 2030 from USD 2.25 billion in 2025, at a CAGR of 9.8%. Healthcare systems are increasingly focused on capturing and analyzing patient data to enhance care quality and meet regulatory requirements. Patient registry software collects disease, procedure, and population data, facilitating clinical research and population health management. These platforms are vital for generating real-world evidence to support drug assessments and value-based care, ultimately reducing healthcare costs and driving market growth.

世界の患者登録ソフトウェア市場は、2025年の22億5,000万米ドルから2030年には36億1,000万米ドルに達し、年平均成長率（CAGR）9.8%で成長すると予測されています。医療システムは、ケアの質を高め、規制要件を満たすために、患者データの収集と分析にますます重点を置いています。患者登録ソフトウェアは、疾患、処置、および人口データを収集し、臨床研究と集団健康管理を促進します。これらのプラットフォームは、薬剤評価と価値に基づくケアを裏付けるリアルワールドエビデンスの生成に不可欠であり、最終的には医療費の削減と市場の成長を促進します。

“The direct-to-patient registries segment is expected to witness the highest growth during the forecast period.”

The patient registry software market is divided into direct-to-patient and site-based/clinical data registries. Direct-to-patient registries are expected to register the highest CAGR due to increased patient engagement, adoption of digital health tools (like ePRO and mobile apps), demand for real-world evidence from patients, and the rise of decentralized clinical trials that focus on patient-reported outcomes. Virtual platforms simplify data collection, easing the burden on healthcare providers and allowing for better longitudinal follow-up and diverse patient recruitment.

“The medical research & clinical studies segment held the largest share of the patient registry software market, by use case, in 2024.”

In 2024, the medical research & clinical studies segment dominated the patient registry software market. This growth is largely driven by the increasing use of real-world data (RWD) and real-world evidence (RWE) for clinical trials and drug development. Patient registry software captures structured and longitudinal patient data, helping researchers analyze outcomes and monitor safety. The rise of personalized medicine and collaborations among life science companies, academic centers, and public health agencies further enhances the need for robust registry infrastructure. The shift toward decentralized trials and post-marketing surveillance also reinforces this segment’s leading position.

“North America accounted for the largest share of the patient registry software market in 2024.”

In 2024, North America held the largest share of the patient registry software market, driven by strong regulatory frameworks and early digital health adoption. Key players like MRO Corp and ImageTrend enhance competition and innovation. Federal initiatives, such as the US HHS’s data modernization and the CDC’s focus on chronic disease surveillance, increase the demand for registry platforms. Notably, in February 2025, Veradigm and HealthVerity partnered to integrate cardiovascular and metabolic data with HealthVerity’s privacy-compliant platform, enabling comprehensive research on patient journeys. Additionally, in April 2024, ESO Solutions acquired Logis Solutions to improve data-driven emergency response, enhancing interoperability and patient outcomes. These developments solidify North America’s leadership in patient registry software innovation and data integration.

The breakdown of primary participants is listed below:

• By Company Type: Tier 1 (45%), Tier 2 (30%), and Tier 3 (25%)
• By Designation: C-level Executives (42%), Directors (31%), and Others (27%)
• By Region: North America (35%), Europe (30%), Asia Pacific (25%), the Middle East & Africa (5%), and Latin America (5%)

Key Players in the Patient Registry Software Market

The key players in the patient registry software market include IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), Elekta (Sweden), Dassault Systemes (France), EvidentIQ (Dacima Software Inc.) (Germany), MRO (Figmd, Inc.) (US), ImageTrend, Inc. (US), Global Vision Technologies, Inc. (US), Syneos Health (US), Veradigm LLC (US), ESO (US), Ordinal Data, Inc. (US), NEC Corporation (NEC Software Solutions UK Limited) (Japan), Cedaron Medical (US), Fivos Health (US), and Across Health (US).

Research Coverage

The report analyzes the patient registry software market. Its objective is to estimate the market size and future growth potential of various segments, categorized by product, registry type, use case, deployment model, end user, and region. Additionally, the report includes a competitive analysis of the key players in this market, featuring their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will help both established companies and new or smaller firms assess the market’s current state, enabling them to capture a larger market share. Organizations that purchase this report can utilize one or more of the strategies outlined below to enhance their market positions.

This report provides insights on:

Analysis of Key Drivers: Drivers (growing demand for real-world evidence (RWE) and rising incidence of chronic and rare diseases), restraints (high setup and operational costs and limited access in low-resource settings), opportunities [integration with AI and analytics tools and expanding use in decentralized clinical trials (DCTs)], and challenges (inconsistent data quality and completeness and limited workforce expertise) influencing the growth of the patient registry software market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the patient registry software market.
• Market Development: Comprehensive information on the lucrative emerging markets, products, use cases, registry types, deployment models, end users, and regions.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the patient registry software market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the patient registry software market, such as IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), and Elekta (Sweden).

Table of Contents

1               INTRODUCTION              34

1.1           STUDY OBJECTIVES       34

1.2           MARKET DEFINITION   34

1.3           MARKET SCOPE                35

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 35

1.3.2        INCLUSIONS & EXCLUSIONS       36

1.3.3        YEARS CONSIDERED      37

1.4           CURRENCY CONSIDERED            37

1.5           LIMITATIONS    38

1.6           STAKEHOLDERS               38

1.7           SUMMARY OF CHANGES               39

2               RESEARCH METHODOLOGY       40

2.1           RESEARCH DATA              40

2.1.1        SECONDARY DATA          41

2.1.1.1    Key data from secondary sources       41

2.1.2        PRIMARY DATA 42

2.1.2.1    Key data from primary sources           43

2.1.2.2    Breakdown of primary sources           44

2.2           RESEARCH METHODOLOGY DESIGN     45

2.3           MARKET SIZE ESTIMATION         46

2.4           MARKET BREAKDOWN & DATA TRIANGULATION                 52

2.5           RESEARCH ASSUMPTIONS           53

2.5.1        MARKET SIZING ASSUMPTIONS                53

2.5.2        OVERALL STUDY ASSUMPTIONS              54

2.6           RISK ASSESSMENT           54

2.7           RESEARCH LIMITATIONS             55

2.7.1        METHODOLOGY-RELATED LIMITATIONS           55

2.7.2        SCOPE-RELATED LIMITATIONS                 55

3               EXECUTIVE SUMMARY  56

4               PREMIUM INSIGHTS       62

4.1           PATIENT REGISTRY SOFTWARE MARKET OVERVIEW                 62

4.2           NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT & REGION           63

4.3           PATIENT REGISTRY SOFTWARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         64

4.4           PATIENT REGISTRY SOFTWARE MARKET: DEVELOPED VS. EMERGING ECONOMIES       65

5               MARKET OVERVIEW       66

5.1           INTRODUCTION              66

5.2           MARKET DYNAMICS       66

5.2.1        MARKET DYNAMICS       68

5.2.1.1    Rising burden of chronic and rare diseases      68

5.2.1.2    Shift toward value-based and patient-centered care       68

5.2.1.3    Expansion of real-world evidence (RWE) and post-marketing surveillance needs 69

5.2.1.4    Increasing use of digital health technologies and interoperable EHRs      69

5.2.1.5    Government and regulatory incentives for registry implementation     70

5.2.2        MARKET RESTRAINTS   70

5.2.2.1    Shortage of trained and skilled resources         70

5.2.2.2    High implementation and maintenance costs 71

5.2.3        MARKET OPPORTUNITIES           71

5.2.3.1    Expansion of population health management and outcomes tracking  71

5.2.3.2    Rising demand for pregnancy and congenital anomaly registries for maternal-fetal safety monitoring 72

5.2.3.3    Growing preference for subscription-based deployment models                 72

5.2.4        MARKET CHALLENGES 73

5.2.4.1    Privacy- and data security-related concerns    73

5.2.4.2    Reluctance to adopt advanced patient registry solutions                 74

5.2.4.3    Limited awareness among healthcare stakeholders         74

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       74

5.4           INDUSTRY TRENDS         75

5.4.1        STRENGTHENED FUNDING FOR PATIENT-CENTERED RESEARCH AND RARE DISEASE REGISTRIES        75

5.4.2        RISE IN AUTOMATED DATA ENTRY AND REGISTRY INTELLIGENCE 75

5.4.3        CLOUD-BASED REGISTRIES AND DECENTRALIZED ACCESS 76

5.5           ECOSYSTEM ANALYSIS  77

5.6           VALUE CHAIN ANALYSIS               80

5.7           TECHNOLOGY ANALYSIS             82

5.7.1        KEY TECHNOLOGIES     82

5.7.1.1    Electronic data capture (EDC) systems            82

5.7.1.2    Cloud computing & SaaS architecture               83

5.7.1.3    Data privacy & security technologies                 83

5.7.2        COMPLEMENTARY TECHNOLOGIES       84

5.7.2.1    Electronic health record (EHR) systems          84

5.7.2.2    Clinical trial management systems (CTMS)    84

5.7.3        ADJACENT TECHNOLOGIES       84

5.7.3.1    Digital therapeutics (DTx) platforms                84

5.7.3.2    Wearable devices & remote monitoring tools  85

5.7.3.3    Blockchain for health data management           85

5.8           REGULATORY ANALYSIS               86

5.8.1        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             86

5.8.2        REGULATORY LANDSCAPE         88

5.8.2.1    North America      88

5.8.2.2    Europe   90

5.8.2.3    Asia Pacific            91

5.8.2.4    Middle East & Africa            92

5.8.2.5    Latin America       92

5.9           PRICING ANALYSIS          93

5.9.1        AVERAGE COST OF PATIENT REGISTRY SOFTWARE, BY END USER (2024)               93

5.9.2        INDICATIVE PRICE OF PATIENT REGISTRY SOFTWARE, BY REGION (2024)             94

5.10         PORTER’S FIVE FORCES ANALYSIS           94

5.10.1      INTENSITY OF COMPETITIVE RIVALRY 95

5.10.2      BARGAINING POWER OF BUYERS             96

5.10.3      THREAT OF SUBSTITUTES          96

5.10.4      THREAT OF NEW ENTRANTS      96

5.10.5      BARGAINING POWER OF SUPPLIERS       96

5.11         PATENT ANALYSIS          96

5.11.1      PATENT PUBLICATION TRENDS FOR PATIENT REGISTRY SOFTWARE MARKET 97

5.11.2      JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PATIENT REGISTRY SOFTWARE      97

5.11.3      MAJOR PATENTS IN PATIENT REGISTRY SOFTWARE MARKET               98

5.12         KEY STAKEHOLDERS & BUYING CRITERIA            100

5.12.1      KEY STAKEHOLDERS IN BUYING PROCESS           100

5.12.2      KEY BUYING CRITERIA  101

5.13         END-USER ANALYSIS      102

5.13.1      UNMET NEEDS 102

5.13.2      END-USER EXPECTATIONS         102

5.14         KEY CONFERENCES & EVENTS, 2025–2026              103

5.15         CASE STUDY ANALYSIS 105

5.16         INVESTMENT & FUNDING SCENARIO     107

5.17         BUSINESS MODEL ANALYSIS      107

5.18         IMPACT OF AI/GEN AI ON PATIENT REGISTRY SOFTWARE MARKET       108

5.18.1      TOP USE CASES & MARKET POTENTIAL                 108

5.18.2      KEY USE CASES 110

5.18.3      CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION         110

5.18.3.1  Case study: AI-powered data summarization improves registry utilization efficiency             110

5.18.4      ELECTRONIC HEALTH RECORD (EHR) MARKET                 112

5.18.5      REAL WORLD EVIDENCE (RWE) MARKET              112

5.18.6      USER READINESS AND IMPACT ASSESSMENT     112

5.18.6.1  User readiness       112

5.18.6.1.1                Hospitals & research networks           112

5.18.6.2  Impact assessment                112

5.18.6.2.1                Hospitals & academic research institutes          112

5.18.6.2.1.1            Implementation    112

5.18.6.2.1.2            Impact    113

5.19         IMPACT OF 2025 US TARIFFS ON PATIENT REGISTRY SOFTWARE MARKET       113

5.19.1      INTRODUCTION              113

5.19.2      KEY TARIFF RATES          114

5.19.3      PRICE IMPACT ANALYSIS             115

5.19.3.1  Cloud hosting infrastructure               115

5.19.3.2  AI & analytics modules        115

5.19.3.3  Offshore development & support services        115

5.19.4      IMPACT ON COUNTRY/REGION                115

5.19.4.1  US           115

5.19.4.2  Europe   115

5.19.4.3  Asia Pacific            115

5.19.5      IMPACT ON END-USE INDUSTRIES          116

5.19.5.1  For-profit registries              116

5.19.5.2  Nonprofit registries              116

5.19.5.3  Government & third-party administrators       117

5.19.5.4  Others    117

6               PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE     118

6.1           INTRODUCTION              119

6.2           DISEASE REGISTRIES      119

6.2.1        DIABETES REGISTRIES  121

6.2.1.1    Need to monitor disease prevalence, treatment adherence, and long-term complications to boost adoption      121

6.2.2        CARDIOVASCULAR REGISTRIES 121

6.2.2.1    Ability of cardiovascular registries to enable healthcare systems to benchmark care quality and identify treatment gaps to boost growth                 121

6.2.3        CANCER REGISTRIES      122

6.2.3.1    Critical tools for understanding cancer epidemiology and evaluating screening programs to drive market               122

6.2.4        RARE DISEASE REGISTRIES          123

6.2.4.1    Essential tools for advancing knowledge about rare diseases to support market growth        123

6.2.5        ASTHMA REGISTRIES     124

6.2.5.1    Improving asthma management and reducing exacerbations to fuel growth             124

6.2.6        CHRONIC KIDNEY REGISTRIES  125

6.2.6.1    Ability of registries to collect detailed data on disease progression, lab results, and treatment adherence to boost adoption 125

6.2.7        ORTHOPEDIC REGISTRIES          125

6.2.7.1    Ability to monitor implant performance, surgical outcomes, and complication rates to drive growth    125

6.2.8        IMMUNIZATION REGISTRIES      126

6.2.8.1    Strengthening vaccine coverage and safety monitoring to propel market    126

6.2.9        BIRTH DEFECT REGISTRIES        127

6.2.9.1    Need to track and prevent congenital anomalies through birth defect registries to propel market growth         127

6.2.10      OTHER DISEASE REGISTRIES      128

6.3           PRODUCT REGISTRIES  129

6.3.1        MEDICAL DEVICE REGISTRIES  130

6.3.1.1    Ability of these registries to enhance safety, performance monitoring, and regulatory compliance to boost growth                130

6.3.2        DRUG REGISTRIES           131

6.3.2.1    Ability to support long-term safety, real-world evidence, and optimal therapy use to propel growth                131

7               PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT                 132

7.1           INTRODUCTION              133

7.2           DIRECT-TO-PATIENT (PATIENT-RECORDED) REGISTRIES        133

7.2.1        INCREASING PATIENT ENGAGEMENT AND DEMAND FOR SELF-REPORTED DATA TO BOOST MARKET GROWTH                 133

7.3           SITE-BASED/CLINICAL DATA (PROVIDER-RECORDED) REGISTRIES        134

7.3.1        GROWING NEED FOR ACCURATE, CLINICIAN-VERIFIED DATA AND SEAMLESS EHR INTEGRATION TO SUPPORT GROWTH             134

8               PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE                 136

8.1           INTRODUCTION              137

8.2           MEDICAL RESEARCH & CLINICAL STUDIES          137

8.2.1        GROWING NEED TO LEVERAGE REGISTRIES TO ENHANCE REAL-WORLD EVIDENCE AND CLINICAL TRIAL EFFICIENCY TO FUEL GROWTH                 137

8.3           QUALITY IMPROVEMENT            138

8.3.1        ADVANTAGES SUCH AS EVIDENCE-BASED PRACTICE AND PERFORMANCE BENCHMARKING TO DRIVE SEGMENTAL GROWTH             138

8.4           PATIENT CARE MANAGEMENT 139

8.4.1        ABILITY TO EMPOWER PROACTIVE CHRONIC DISEASE MANAGEMENT THROUGH CENTRALIZED REGISTRIES TO SUPPORT GROWTH        139

8.5           POPULATION HEALTH 140

8.5.1        EXPANDING ROLE OF PATIENT MANAGEMENT SYSTEMS IN DRIVING DIGITAL TRANSFORMATION TO CONTRIBUTE TO GROWTH         140

8.6           POINT-OF-CARE SUPPORT          141

8.6.1        NEED FOR PERSONALIZED TREATMENT PLANS AND SHARED DECISION-MAKING TO DRIVE EFFICIENCY AND QUALITY IN HEALTHCARE          141

8.7           PUBLIC HEALTH SURVEILLANCE              142

8.7.1        ABILITY OF REGISTRIES TO ENHANCE PREPAREDNESS AND RESPONSE CAPABILITIES TO DRIVE SEGMENTAL GROWTH                 142

8.8           PATIENT SELF-CARE      143

8.8.1        GROWING EMPHASIS ON PATIENT EMPOWERMENT AND SELF-MANAGEMENT TO PROPEL GROWTH              143

8.9           PATIENT ENGAGEMENT               144

8.9.1        ADVANTAGES SUCH AS BETTER DATA ACCURACY AND MORE MEANINGFUL OUTCOMES TO BOOST GROWTH 144

8.10         OTHER USE CASES           145

9               PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT  147

9.1           INTRODUCTION              148

9.2           ON-PREMISE MODELS   148

9.2.1        GROWING DEMAND FOR SECURITY, CONTROL, AND COMPLIANCE TO DRIVE MARKET GROWTH       148

9.3           CLOUD-BASED MODELS               149

9.3.1        SCALABILITY, INTEROPERABILITY, AND COST-EFFECTIVENESS OF CLOUD-BASED MODELS TO DRIVE GROWTH             149

10            PATIENT REGISTRY SOFTWARE MARKET, BY END USER                 151

10.1         INTRODUCTION              152

10.2         FOR-PROFIT REGISTRIES              152

10.2.1      PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDTECH COMPANIES       153

10.2.1.1  Need for robust evidence generation, enhanced patient safety, and competitive differentiation to drive adoption           153

10.2.2      HEALTHCARE PAYERS   154

10.2.2.1  Need to improve population health management, control costs, and assess treatment value to drive demand    154

10.2.3      HEALTHCARE PROVIDERS           155

10.2.3.1  Hospitals                156

10.2.3.1.1                Ability of registries to help hospitals collect detailed data on procedures, outcomes, and complications to boost market      156

10.2.3.2  Clinics & outpatient settings               157

10.2.3.2.1                Ability of registries to enable data-driven decision-making and streamlined documentation to drive demand             157

10.2.3.3  Other healthcare providers 158

10.3         NONPROFIT REGISTRIES              159

10.3.1      MEDICAL SPECIALTY SOCIETIES              160

10.3.1.1  Advantages such as defined best practices and improved care delivery to propel growth    160

10.3.2      PATIENT ORGANIZATIONS         161

10.3.2.1  Importance of facilitating clinical trial recruitment and fostering collaboration with researchers to support growth            161

10.4         GOVERNMENT & THIRD-PARTY ADMINISTRATORS                 162

10.4.1      ABILITY OF GOVERNMENT-RUN REGISTRIES TO EVALUATE SUCCESS OF HEALTHCARE INITIATIVES TO FUEL MARKET               162

10.5         OTHER END USERS         163

11            PATIENT REGISTRY SOFTWARE MARKET, BY REGION                 165

11.1         INTRODUCTION              166

11.2         NORTH AMERICA             166

11.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 167

11.2.2      US           172

11.2.2.1  US to dominate global market for patient registry software                 172

11.2.3      CANADA               177

11.2.3.1  Government investment, collaborative initiatives, and strong push to standardize rare disease registries to drive growth            177

11.3         EUROPE               182

11.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      183

11.3.2      UK          189

11.3.2.1  Growing incidence of cancer to drive market growth     189

11.3.3      GERMANY           194

11.3.3.1  National rollout of e-patient files and rare disease registries to strengthen patient care and research                 194

11.3.4      FRANCE                198

11.3.4.1  Growing patient registry adoption with national data platforms and rare disease initiatives to support market growth    198

11.3.5      ITALY    203

11.3.5.1  Growing number of national networks and disease-specific registries to drive growth    203

11.3.6      SPAIN    207

11.3.6.1  Growing need to address rising chronic and cardiovascular disease prevalence to drive adoption 207

11.3.7      REST OF EUROPE             212

11.4         ASIA PACIFIC     216

11.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 216

11.4.2      JAPAN   223

11.4.2.1  Japan’s aging population and advanced digital strategies to drive growth in patient registry software market       223

11.4.3      CHINA  228

11.4.3.1  Robust national registries and expanding pharmaceutical approvals to drive patient registry software market        228

11.4.4      INDIA    233

11.4.4.1  Digital health advances to boost India’s patient registry software market    233

11.4.5      REST OF ASIA PACIFIC   238

11.5         LATIN AMERICA                243

11.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 243

11.5.2      BRAZIL 249

11.5.2.1  Brazil to dominate patient registry software market in Latin America 249

11.5.3      MEXICO                254

11.5.3.1  Increase in focus of digital health to boost market growth                 254

11.5.4      REST OF LATIN AMERICA             259

11.6         MIDDLE EAST & AFRICA                264

11.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 264

11.6.2      GCC COUNTRIES              270

11.6.2.1  Rising healthcare investments to fuel uptake   270

11.6.3      REST OF MIDDLE EAST & AFRICA             275

12            COMPETITIVE LANDSCAPE         281

12.1         OVERVIEW          281

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            281

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET        281

12.3         REVENUE ANALYSIS, 2020–2024  283

12.4         MARKET SHARE ANALYSIS, 2024                 284

12.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 287

12.5.1      STARS   287

12.5.2      EMERGING LEADERS     287

12.5.3      PERVASIVE PLAYERS      287

12.5.4      PARTICIPANTS 287

12.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         289

12.5.5.1  Company footprint               289

12.5.5.2  Region footprint   290

12.5.5.3  Product footprint  291

12.5.5.4  Use case footprint 292

12.5.5.5  Registry type footprint         293

12.5.5.6  Deployment footprint          294

12.5.5.7  End-user footprint                295

12.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        296

12.6.1      PROGRESSIVE COMPANIES         296

12.6.2      RESPONSIVE COMPANIES            296

12.6.3      DYNAMIC COMPANIES  296

12.6.4      STARTING BLOCKS         296

12.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 298

12.6.5.1  Detailed list of key startups/SMEs    298

12.6.5.2  Competitive benchmarking of startups/Smes 298

12.7         COMPANY VALUATION & FINANCIAL METRICS 299

12.7.1      FINANCIAL METRICS      299

12.7.2      COMPANY VALUATION 299

12.8         BRAND/SOFTWARE COMPARISON           300

12.9         COMPETITIVE SCENARIO             301

12.9.1      PRODUCT LAUNCHES, APPROVALS, UPGRADES, AND ENHANCEMENTS             301

12.9.2      DEALS  302

12.9.3      OTHER DEVELOPMENTS              303

13            COMPANY PROFILES      304

13.1         KEY PLAYERS     304

13.1.1      IBM        304

13.1.1.1  Business overview 304

13.1.1.2  Products offered   305

13.1.1.3  Recent developments           306

13.1.1.3.1                Product enhancements        306

13.1.1.4  MnM view              306

13.1.1.4.1                Right to win           306

13.1.1.4.2                Strategic choices   306

13.1.1.4.3                Weaknesses & competitive threats     307

13.1.2      IQVIA HOLDINGS INC.   308

13.1.2.1  Business overview 308

13.1.2.2  Products offered   309

13.1.2.3  Recent developments           310

13.1.2.3.1                Deals      310

13.1.2.4  MnM view              310

13.1.2.4.1                Right to win           310

13.1.2.4.2                Strategic choices   311

13.1.2.4.3                Weaknesses & competitive threats     311

13.1.3      HEALTH CATALYST, INC.             312

13.1.3.1  Business overview 312

13.1.3.2  Products offered   313

13.1.3.3  Recent developments           314

13.1.3.3.1                Product approvals 314

13.1.3.3.2                Deals      314

13.1.3.3.3                Other developments             315

13.1.3.4  MnM view              315

13.1.3.4.1                Right to win           315

13.1.3.4.2                Strategic choices   315

13.1.3.4.3                Weaknesses & competitive threats     316

13.1.4      ORACLE                317

13.1.4.1  Business overview 317

13.1.4.2  Products offered   319

13.1.4.3  Recent developments           319

13.1.4.3.1                Deals      319

13.1.4.4  MnM view              319

13.1.4.4.1                Right to win           319

13.1.4.4.2                Strategic choices   320

13.1.4.4.3                Weaknesses & competitive threats     320

13.1.5      UNITEDHEALTH GROUP              321

13.1.5.1  Business overview 321

13.1.5.2  Products offered   322

13.1.5.3  Recent developments           323

13.1.5.3.1                Deals      323

13.1.5.4  MnM view              323

13.1.5.4.1                Right to win           323

13.1.5.4.2                Strategic choices   323

13.1.5.4.3                Weaknesses & competitive threats     323

13.1.6      CONDUENT INCORPORATED    324

13.1.6.1  Business overview 324

13.1.6.2  Products offered   326

13.1.6.3  Recent developments           326

13.1.6.3.1                Deals      326

13.1.7      ELEKTA                328

13.1.7.1  Business overview 328

13.1.7.2  Products offered   329

13.1.7.3  Recent developments           330

13.1.7.3.1                Deals      330

13.1.8      NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED)             331

13.1.8.1  Business overview 331

13.1.8.2  Products offered   333

13.1.9      DASSAULT SYSTÈMES (MEDIDATA)        334

13.1.9.1  Business overview 334

13.1.9.2  Products offered   336

13.1.9.3  Recent developments           336

13.1.9.3.1                Product launches  336

13.1.9.3.2                Deals      337

13.1.10   EVIDENTIQ (DACIMA SOFTWARE INC.) 338

13.1.10.1                 Business overview 338

13.1.10.2                 Products offered   338

13.1.10.3                 Recent developments           339

13.1.10.3.1             DEALS  339

13.1.11   MRO (FIGMD, INC.)         340

13.1.11.1                 Business overview 340

13.1.11.2                 Products offered   341

13.1.11.3                 Recent developments           342

13.1.11.3.1             Deals      342

13.1.11.3.2             Other developments             342

13.1.12   IMAGETREND   343

13.1.12.1                 Business overview 343

13.1.12.2                 Products offered   343

13.1.12.3                 Recent developments           344

13.1.12.3.1             Product upgrades 344

13.1.12.3.2             Deals      344

13.1.13   GLOBAL VISION TECHNOLOGIES, INC. 346

13.1.13.1                 Business overview 346

13.1.13.2                 Products offered   346

13.1.13.3                 Recent developments           347

13.1.13.3.1             Other developments             347

13.1.14   SYNEOS HEALTH              348

13.1.14.1                 Business overview 348

13.1.14.2                 Products offered   349

13.1.14.3                 Recent developments           350

13.1.14.3.1             Deals      350

13.1.15   VERADIGM LLC 351

13.1.15.1                 Business overview 351

13.1.15.2                 Products offered   352

13.1.15.3                 Recent developments           354

13.1.15.3.1             Product launches  354

13.1.15.3.2             Deals      355

13.1.16   ESO        356

13.1.16.1                 Business overview 356

13.1.16.2                 Products offered   356

13.1.16.3                 Recent developments           357

13.1.16.3.1             Deals      357

13.1.17   ORDINAL DATA INC.      358

13.1.17.1                 Business overview 358

13.1.17.2                 Products offered   358

13.1.18   CEDARON MEDICAL       360

13.1.18.1                 Business overview 360

13.1.18.2                 Products offered   360

13.1.19   FIVOS HEALTH 362

13.1.19.1                 Business overview 362

13.1.19.2                 Products offered   363

13.1.19.3                 Recent developments           364

13.1.19.3.1             Deals      364

13.1.20   ACROSS HEALTHCARE  365

13.1.20.1                 Business overview 365

13.1.20.2                 Products offered   365

13.1.20.3                 Recent developments           366

13.1.20.3.1             Deals      366

13.2         OTHER PLAYERS              367

13.2.1      VERANA HEALTH             367

13.2.2      PULSE INFOFRAME INC.                368

13.2.3      AMPLITUDE CLINICAL OUTCOMES         369

13.2.4      NPHASE, INC. (REDCAP CLOUD)               370

13.2.5      OM1       371

14            APPENDIX           372

14.1         DISCUSSION GUIDE        372

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                377

14.3         CUSTOMIZATION OPTIONS        379

14.4         RELATED REPORTS         379

14.5         AUTHOR DETAILS           380

LIST OF TABLES

TABLE 1                EXCHANGE RATES UTILIZED FOR CONVERSION TO USD                38

TABLE 2                FACTOR ANALYSIS          50

TABLE 3                RISK ASSESSMENT: PATIENT REGISTRY SOFTWARE MARKET       54

TABLE 4                PATIENT REGISTRY SOFTWARE MARKET: IMPACT ANALYSIS           67

TABLE 5                HEALTHCARE DATA BREACHES IN US   73

TABLE 6                PATIENT REGISTRY SOFTWARE MARKET: ROLE IN ECOSYSTEM 79

TABLE 7                NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  86

TABLE 8                EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 87

TABLE 9                ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  87

TABLE 10              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  88

TABLE 11              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  88

TABLE 12              REGULATORY SCENARIO OF NORTH AMERICA                 88

TABLE 13              REGULATORY SCENARIO OF EUROPE    90

TABLE 14              REGULATORY SCENARIO OF ASIA PACIFIC                 91

TABLE 15              REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 92

TABLE 16              REGULATORY SCENARIO OF LATIN AMERICA                 92

TABLE 17              AVERAGE COST OF PATIENT REGISTRY SOFTWARE, BY END USER

(ORDINAL HEALTH INC.) (2024)                 93

TABLE 18              INDICATIVE PRICE RANGE OF PATIENT REGISTRY SOFTWARE, BY REGION (2024)              94

TABLE 19              PATIENT REGISTRY SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS           95

TABLE 20              JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR PATIENT

REGISTRY SOFTWARE   98

TABLE 21              PATIENT REGISTRY SOFTWARE MARKET: LIST OF PATENTS/PATENT APPLICATIONS   99

TABLE 22              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE

END USERS (%) 100

TABLE 23              KEY BUYING CRITERIA FOR TOP THREE END USERS   101

TABLE 24              UNMET NEEDS IN PATIENT REGISTRY SOFTWARE MARKET       102

TABLE 25              END-USER EXPECTATIONS IN PATIENT REGISTRY SOFTWARE MARKET 103

TABLE 26              PATIENT REGISTRY SOFTWARE MARKET: KEY CONFERENCES & EVENTS,

2025–2026              104

TABLE 27              CASE STUDY 1: CANCER REGISTRY IMPLEMENTATION WITH

DACIMA CLINICAL SUITE             105

TABLE 28              CASE STUDY 2: ENHANCING REAL-WORLD EVIDENCE WITH CASTOR RWE  106

TABLE 29              CASE STUDY 3: DEVICE DATA INTEGRATION USING MEDIREPORT 360               106

TABLE 30              US-ADJUSTED RECIPROCAL TARIFF RATES                 114

TABLE 31              PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            119

TABLE 32              PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         120

TABLE 33              PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   120

TABLE 34              PATIENT REGISTRY SOFTWARE MARKET FOR DIABETES REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   121

TABLE 35              PATIENT REGISTRY SOFTWARE MARKET FOR CARDIOVASCULAR REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   122

TABLE 36              PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REGISTRIES, BY REGION, 2023–2030 (USD MILLION)                 123

TABLE 37              PATIENT REGISTRY SOFTWARE MARKET FOR RARE DISEASE REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   124

TABLE 38              PATIENT REGISTRY SOFTWARE MARKET FOR ASTHMA REGISTRIES, BY REGION, 2023–2030 (USD MILLION)                 124

TABLE 39              PATIENT REGISTRY SOFTWARE MARKET FOR CHRONIC KIDNEY REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   125

TABLE 40              PATIENT REGISTRY SOFTWARE MARKET FOR ORTHOPEDIC REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   126

TABLE 41              PATIENT REGISTRY SOFTWARE MARKET FOR IMMUNIZATION REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   127

TABLE 42              PATIENT REGISTRY SOFTWARE MARKET FOR BIRTH DEFECT REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   128

TABLE 43              PATIENT REGISTRY SOFTWARE MARKET FOR OTHER DISEASE REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   128

TABLE 44              PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)                 129

TABLE 45              PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY REGION, 2023–2030 (USD MILLION)                 129

TABLE 46              PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL DEVICE REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   130

TABLE 47              PATIENT REGISTRY SOFTWARE MARKET FOR DRUG REGISTRIES, BY REGION, 2023–2030 (USD MILLION)                 131

TABLE 48              PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            133

TABLE 49              PATIENT REGISTRY SOFTWARE MARKET FOR DIRECT-TO-PATIENT (PATIENT-RECORDED) REGISTRIES, BY REGION, 2023–2030 (USD MILLION)          134

TABLE 50              PATIENT REGISTRY SOFTWARE MARKET FOR SITE-BASED/CLINICAL DATA (PROVIDER-RECORDED) REGISTRIES, BY REGION, 2023–2030 (USD MILLION)         135

TABLE 51              PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            137

TABLE 52              PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY REGION, 2023–2030 (USD MILLION)       138

TABLE 53              PATIENT REGISTRY SOFTWARE MARKET FOR QUALITY IMPROVEMENT, BY REGION, 2023–2030 (USD MILLION)            139

TABLE 54              PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT,

BY REGION, 2023–2030 (USD MILLION)   140

TABLE 55              PATIENT REGISTRY SOFTWARE MARKET FOR POPULATION HEALTH, BY REGION, 2023–2030 (USD MILLION)                 141

TABLE 56              PATIENT REGISTRY SOFTWARE MARKET FOR POINT-OF-CARE SUPPORT,

BY REGION, 2023–2030 (USD MILLION)   142

TABLE 57              PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC HEALTH SURVEILLANCE,

BY REGION, 2023–2030 (USD MILLION)   143

TABLE 58              PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT SELF-CARE, BY REGION, 2023–2030 (USD MILLION)                 144

TABLE 59              PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT ENGAGEMENT,

BY REGION, 2023–2030 (USD MILLION)   145

TABLE 60              PATIENT REGISTRY SOFTWARE MARKET FOR OTHER USE CASES, BY REGION, 2023–2030 (USD MILLION)                 146

TABLE 61              PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            148

TABLE 62              PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS,

BY REGION, 2023–2030 (USD MILLION)   149

TABLE 63              PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS,

BY REGION, 2023–2030 (USD MILLION)   150

TABLE 64              PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            152

TABLE 65              PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         153

TABLE 66              PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   153

TABLE 67              PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDTECH COMPANIES, BY REGION, 2023–2030 (USD MILLION)        154

TABLE 68              PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PAYERS, BY REGION, 2023–2030 (USD MILLION)                 155

TABLE 69              PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         156

TABLE 70              PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY REGION, 2023–2030 (USD MILLION)   156

TABLE 71              PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS, BY REGION,

2023–2030 (USD MILLION)            157

TABLE 72              PATIENT REGISTRY SOFTWARE MARKET FOR CLINICS & OUTPATIENT SETTINGS,

BY REGION, 2023–2030 (USD MILLION)   158

TABLE 73              PATIENT REGISTRY SOFTWARE MARKET FOR OTHER HEALTHCARE PROVIDERS,

BY REGION, 2023–2030 (USD MILLION)   159

TABLE 74              PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         159

TABLE 75              PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY REGION, 2023–2030 (USD MILLION)   160

TABLE 76              PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL SPECIALTY SOCIETIES,

BY REGION, 2023–2030 (USD MILLION)   161

TABLE 77              PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT ORGANIZATIONS,

BY REGION, 2023–2030 (USD MILLION)   162

TABLE 78              PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT & THIRD-PARTY ADMINISTRATORS, BY REGION, 2023–2030 (USD MILLION)            163

TABLE 79              PATIENT REGISTRY SOFTWARE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)                 164

TABLE 80              PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)          166

TABLE 81              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            168

TABLE 82              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            168

TABLE 83              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            169

TABLE 84              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023–2030 (USD MILLION)            169

TABLE 85              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       170

TABLE 86              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       170

TABLE 87              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION)            171

TABLE 88              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            171

TABLE 89              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            171

TABLE 90              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            172

TABLE 91              NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            172

TABLE 92              US: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            173

TABLE 93              US: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            174

TABLE 94              US: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            174

TABLE 95              US: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)                 175

TABLE 96              US: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)                 175

TABLE 97              US: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            176

TABLE 98              US: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            176

TABLE 99              US: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         176

TABLE 100            US: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         177

TABLE 101            US: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         177

TABLE 102            CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            178

TABLE 103            CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            179

TABLE 104            CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            179

TABLE 105            CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         180

TABLE 106            CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         180

TABLE 107            CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            181

TABLE 108            CANADA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            181

TABLE 109            CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION) 181

TABLE 110            CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 182

TABLE 111            CANADA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         182

TABLE 112            EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            185

TABLE 113            EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            185

TABLE 114            EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            186

TABLE 115            EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            186

TABLE 116            EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         187

TABLE 117            EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         187

TABLE 118            EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            188

TABLE 119            EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            188

TABLE 120            EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION) 188

TABLE 121            EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 189

TABLE 122            EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         189

TABLE 123            UK: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            190

TABLE 124            UK: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)          190

TABLE 125            UK: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            191

TABLE 126            UK: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         191

TABLE 127            UK: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         192

TABLE 128            UK: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            192

TABLE 129            UK: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            192

TABLE 130            UK: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         193

TABLE 131            UK: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         193

TABLE 132            UK: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         193

TABLE 133            GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            194

TABLE 134            GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            195

TABLE 135            GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            195

TABLE 136            GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         196

TABLE 137            GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         196

TABLE 138            GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            197

TABLE 139            GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            197

TABLE 140            GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION) 197

TABLE 141            GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 198

TABLE 142            GERMANY: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION) 198

TABLE 143            FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            199

TABLE 144            FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            199

TABLE 145            FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            200

TABLE 146            FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         200

TABLE 147            FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         201

TABLE 148            FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            201

TABLE 149            FRANCE: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            201

TABLE 150            FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         202

TABLE 151            FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 202

TABLE 152            FRANCE: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         202

TABLE 153          ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            203

TABLE 154          ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            204

TABLE 155          ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            204

TABLE 156            ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         205

TABLE 157            ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         205

TABLE 158          ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)          206

TABLE 159          ITALY: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            206

TABLE 160            ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         206

TABLE 161            ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         207

TABLE 162            ITALY: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         207

TABLE 163          SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            208

TABLE 164          SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            208

TABLE 165          SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            209

TABLE 166            SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         209

TABLE 167            SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         210

TABLE 168          SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            210

TABLE 169          SPAIN: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            210

TABLE 170            SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         211

TABLE 171            SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         211

TABLE 172            SPAIN: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         211

TABLE 173            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            212

TABLE 174            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            213

TABLE 175            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023–2030 (USD MILLION)            213

TABLE 176            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       214

TABLE 177            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       214

TABLE 178            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION)            215

TABLE 179            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            215

TABLE 180            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            215

TABLE 181            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            216

TABLE 182            REST OF EUROPE: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            216

TABLE 183            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            218

TABLE 184            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            218

TABLE 185            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            219

TABLE 186            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            219

TABLE 187            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            220

TABLE 188            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            220

TABLE 189            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            221

TABLE 190            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            221

TABLE 191            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION) 222

TABLE 192            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 222

TABLE 193            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION) 222

TABLE 194          JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            223

TABLE 195          JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            224

TABLE 196          JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            224

TABLE 197            JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         225

TABLE 198            JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         225

TABLE 199          JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            226

TABLE 200          JAPAN: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            226

TABLE 201            JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         227

TABLE 202            JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         227

TABLE 203            JAPAN: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         228

TABLE 204            CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            229

TABLE 205            CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            229

TABLE 206            CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            230

TABLE 207            CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         230

TABLE 208            CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         231

TABLE 209            CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            231

TABLE 210            CHINA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            231

TABLE 211            CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         232

TABLE 212            CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         232

TABLE 213            CHINA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         232

TABLE 214          INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            234

TABLE 215          INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            234

TABLE 216          INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            235

TABLE 217            INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         235

TABLE 218            INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         236

TABLE 219          INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            236

TABLE 220          INDIA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            236

TABLE 221            INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         237

TABLE 222            INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         237

TABLE 223            INDIA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         238

TABLE 224            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 239

TABLE 225            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023–2030 (USD MILLION)                 239

TABLE 226            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023–2030 (USD MILLION)            240

TABLE 227            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       240

TABLE 228            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       241

TABLE 229            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION)            241

TABLE 230            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)                 241

TABLE 231            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            242

TABLE 232            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            242

TABLE 233            REST OF ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            243

TABLE 234            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            244

TABLE 235            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            244

TABLE 236            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            245

TABLE 237            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023–2030 (USD MILLION)            245

TABLE 238            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       246

TABLE 239            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       246

TABLE 240            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            247

TABLE 241            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            247

TABLE 242            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            248

TABLE 243            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            248

TABLE 244            LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            248

TABLE 245            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            249

TABLE 246            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            250

TABLE 247            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            250

TABLE 248            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         251

TABLE 249            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         251

TABLE 250            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            252

TABLE 251            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            252

TABLE 252            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         253

TABLE 253            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2023–2030 (USD MILLION)         253

TABLE 254            BRAZIL: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         253

TABLE 255            MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            254

TABLE 256            MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            255

TABLE 257            MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2023–2030 (USD MILLION)            255

TABLE 258            MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         256

TABLE 259            MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         256

TABLE 260            MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2023–2030 (USD MILLION)            257

TABLE 261            MEXICO: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            257

TABLE 262            MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         258

TABLE 263            MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 258

TABLE 264            MEXICO: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES,

BY TYPE, 2023–2030 (USD MILLION)         258

TABLE 265            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 259

TABLE 266            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023–2030 (USD MILLION)                 260

TABLE 267            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET,

BY REGISTRY TYPE, 2023–2030 (USD MILLION)   260

TABLE 268            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       261

TABLE 269            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       261

TABLE 270            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET,

BY DEPLOYMENT, 2023–2030 (USD MILLION)      262

TABLE 271            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET,

BY END USER, 2023–2030 (USD MILLION)               262

TABLE 272            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            263

TABLE 273            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            263

TABLE 274            REST OF LATIN AMERICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            263

TABLE 275            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)                 265

TABLE 276            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 265

TABLE 277            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE, 2023–2030 (USD MILLION)                 266

TABLE 278            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023–2030 (USD MILLION)            266

TABLE 279            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       267

TABLE 280            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       267

TABLE 281            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET,

BY DEPLOYMENT, 2023–2030 (USD MILLION)      268

TABLE 282            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET,

BY END USER, 2023–2030 (USD MILLION)               268

TABLE 283            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            269

TABLE 284            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            269

TABLE 285            MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            269

TABLE 286            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            271

TABLE 287            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2023–2030 (USD MILLION)            271

TABLE 288            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE, 2023–2030 (USD MILLION)            272

TABLE 289            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       272

TABLE 290            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)       273

TABLE 291            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT, 2023–2030 (USD MILLION)            273

TABLE 292            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2023–2030 (USD MILLION)            273

TABLE 293            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            274

TABLE 294            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)            274

TABLE 295            GCC COUNTRIES: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)            274

TABLE 296            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               275

TABLE 297            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET,

BY USE CASE, 2023–2030 (USD MILLION)                276

TABLE 298            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET,

BY REGISTRY TYPE, 2023–2030 (USD MILLION)   276

TABLE 299            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR DISEASE REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)                277

TABLE 300            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)                277

TABLE 301            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET,

BY DEPLOYMENT, 2023–2030 (USD MILLION)      278

TABLE 302            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET,

BY END USER, 2023–2030 (USD MILLION)               278

TABLE 303            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR FOR-PROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)         279

TABLE 304            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)         279

TABLE 305            REST OF MIDDLE EAST & AFRICA: PATIENT REGISTRY SOFTWARE MARKET FOR NONPROFIT REGISTRIES, BY TYPE, 2023–2030 (USD MILLION)         280

TABLE 306            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET, JANUARY 2022–JUNE 2025  281

TABLE 307            PATIENT REGISTRY SOFTWARE MARKET: DEGREE OF COMPETITION         285

TABLE 308            PATIENT REGISTRY SOFTWARE MARKET: REGION FOOTPRINT     290

TABLE 309            PATIENT REGISTRY SOFTWARE MARKET: PRODUCT FOOTPRINT 291

TABLE 310            PATIENT REGISTRY SOFTWARE MARKET: USE CASE FOOTPRINT            292

TABLE 311            PATIENT REGISTRY SOFTWARE MARKET: REGISTRY TYPE FOOTPRINT      293

TABLE 312            PATIENT REGISTRY SOFTWARE MARKET: DEPLOYMENT FOOTPRINT         294

TABLE 313            PATIENT REGISTRY SOFTWARE MARKET: END-USER FOOTPRINT            295

TABLE 314            PATIENT REGISTRY SOFTWARE MARKET: DETAILED LIST OF

KEY STARTUP/SME PLAYERS      298

TABLE 315            PATIENT REGISTRY SOFTWARE MARKET: COMPETITIVE BENCHMARKING

OF KEY EMERGING PLAYERS/STARTUPS, BY PRODUCT AND REGION                298

TABLE 316            PATIENT REGISTRY SOFTWARE MARKET: PRODUCT LAUNCHES, APPROVALS, UPGRADES, AND ENHANCEMENTS, JANUARY 2022–JUNE 2025        301

TABLE 317            PATIENT REGISTRY SOFTWARE MARKET: DEALS, JANUARY 2022–JUNE 2025              302

TABLE 318            PATIENT REGISTRY SOFTWARE MARKET: OTHER DEVELOPMENTS,

JANUARY 2022–JUNE 2025              303

TABLE 319            IBM: COMPANY OVERVIEW         304

TABLE 320            IBM: PRODUCTS OFFERED          305

TABLE 321            IBM: PRODUCT ENHANCEMENTS, JANUARY 2022–JUNE 2025  306

TABLE 322            IQVIA HOLDINGS INC.: COMPANY OVERVIEW                 308

TABLE 323            IQVIA HOLDINGS INC.: PRODUCTS OFFERED                 309

TABLE 324            IQVIA HOLDINGS INC.: DEALS, JANUARY 2022–JUNE 2025             310

TABLE 325            HEALTH CATALYST, INC.: COMPANY OVERVIEW          312

TABLE 326            HEALTH CATALYST, INC.: PRODUCTS OFFERED                 313

TABLE 327            HEALTH CATALYST, INC.: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025   314

TABLE 328            HEALTH CATALYST, INC.: DEALS, JANUARY 2022–JUNE 2025  314

TABLE 329            HEALTH CATALYST, INC.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025         315

TABLE 330            ORACLE: COMPANY OVERVIEW                317

TABLE 331            ORACLE: PRODUCTS OFFERED 319

TABLE 332            ORACLE: DEALS, JANUARY 2022–JUNE 2025                 319

TABLE 333            UNITEDHEALTH GROUP: COMPANY OVERVIEW                 321

TABLE 334            UNITEDHEALTH GROUP: PRODUCTS OFFERED                 322

TABLE 335            UNITEDHEALTH GROUP: DEALS, JANUARY 2022–JUNE 2025  323

TABLE 336            CONDUENT INCORPORATED: COMPANY OVERVIEW          324

TABLE 337            CONDUENT INCORPORATED: PRODUCTS OFFERED             326

TABLE 338            CONDUENT INCORPORATED: DEALS, JANUARY 2022–JUNE 2025  326

TABLE 339            ELEKTA: COMPANY OVERVIEW 328

TABLE 340            ELEKTA: PRODUCTS OFFERED 329

TABLE 341            ELEKTA: DEALS, JANUARY 2022–JUNE 2025                 330

TABLE 342            NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED):

COMPANY OVERVIEW   331

TABLE 343            NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED):

PRODUCTS OFFERED    333

TABLE 344            DASSAULT SYSTÈMES (MEDIDATA): COMPANY OVERVIEW          334

TABLE 345            DASSAULT SYSTÈMES (MEDIDATA): PRODUCTS OFFERED             336

TABLE 346            DASSAULT SYSTÈMES (MEDIDATA): PRODUCT LAUNCHES,

JANUARY 2022–JUNE 2025              336

TABLE 347            DASSAULT SYSTÈMES (MEDIDATA): DEALS, JANUARY 2022–JUNE 2025              337

TABLE 348            EVIDENTIQ (DECIMA SOFTWARE INC.): COMPANY OVERVIEW   338

TABLE 349            EVIDENTIQ (DECIMA SOFTWARE INC.): PRODUCTS OFFERED    338

TABLE 350            EVIDENTIQ (DECIMA SOFTWARE INC.): DEALS, JANUARY 2022–JUNE 2025              339

TABLE 351            MRO (FIGMD, INC.): COMPANY OVERVIEW                 340

TABLE 352            MRO (FIGMD, INC.): PRODUCTS OFFERED                 341

TABLE 353            MRO (FIGMD, INC.): DEALS, JANUARY 2022–JUNE 2025             342

TABLE 354            MRO (FIGMD, INC.): OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025              342

TABLE 355            IMAGETREND: COMPANY OVERVIEW    343

TABLE 356            IMAGETREND: PRODUCTS OFFERED     343

TABLE 357            IMAGETREND: PRODUCT UPGRADES, JANUARY 2022–JUNE 2025  344

TABLE 358            IMAGETREND: DEALS, JANUARY 2022–JUNE 2025                 344

TABLE 359            GLOBAL VISION TECHNOLOGIES, INC.: COMPANY OVERVIEW   346

TABLE 360            GLOBAL VISION TECHNOLOGIES, INC.: PRODUCTS OFFERED    346

TABLE 361            GLOBAL VISION TECHNOLOGIES, INC.: OTHER DEVELOPMENTS ,

JANUARY 2022–JUNE 2025              347

TABLE 362            SYNEOS HEALTH: COMPANY OVERVIEW                 348

TABLE 363            SYNEOS HEALTH: PRODUCTS OFFERED                 349

TABLE 364            SYNEOS HEALTH: DEALS, JANUARY 2022–JUNE 2025        350

TABLE 365            VERADIGM LLC: COMPANY OVERVIEW 351

TABLE 366            VERADIGM LLC: PRODUCTS OFFERED  352

TABLE 367            VERADIGM LLC: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025              354

TABLE 368            VERADIGM LLC: DEALS, JANUARY 2022–JUNE 2025        355

TABLE 369            ESO: COMPANY OVERVIEW         356

TABLE 370            ESO: PRODUCTS OFFERED          356

TABLE 371            ESO: DEALS, JANUARY 2022–JUNE 2025    357

TABLE 372            ORDINAL DATA, INC.: COMPANY OVERVIEW                 358

TABLE 373            ORDINAL DATA, INC.: PRODUCTS OFFERED                 358

TABLE 374            CEDARON MEDICAL: COMPANY OVERVIEW                 360

TABLE 375            CEDARON MEDICAL: PRODUCTS OFFERED                 360

TABLE 376            FIVOS HEALTH: COMPANY OVERVIEW  362

TABLE 377            FIVOS HEALTH: PRODUCTS OFFERED   363

TABLE 378            FIVOS HEALTH: DEALS, JANUARY 2022–JUNE 2025        364

TABLE 379            ACROSS HEALTHCARE: COMPANY OVERVIEW                 365

TABLE 380            ACROSS HEALTHCARE: PRODUCTS OFFERED                 365

TABLE 381            ACROSS HEALTHCARE: DEALS, JANUARY 2022–JUNE 2025             366

LIST OF FIGURES

FIGURE 1              PATIENT REGISTRY SOFTWARE MARKET SEGMENTATION & REGIONAL SCOPE    35

FIGURE 2              RESEARCH DESIGN         40

FIGURE 3              PRIMARY SOURCES         42

FIGURE 4              INSIGHTS FROM INDUSTRY EXPERTS     44

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION     44

FIGURE 6              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           45

FIGURE 7              SUPPLY-SIDE MARKET ESTIMATION      47

FIGURE 8              PATIENT REGISTRY SOFTWARE MARKET: REVENUE ESTIMATION APPROACH         47

FIGURE 9              BOTTOM-UP APPROACH: END-USER SPENDING ON PATIENT REGISTRY SOFTWARE        49

FIGURE 10            CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030)          51

FIGURE 11            CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 51

FIGURE 12            TOP-DOWN APPROACH                52

FIGURE 13            DATA TRIANGULATION METHODOLOGY                 53

FIGURE 14            PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT,

2025 VS. 2030 (USD MILLION)      57

FIGURE 15            PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE,

2025 VS. 2030 (USD MILLION)      58

FIGURE 16            PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE,

2025 VS. 2030 (USD MILLION)      59

FIGURE 17            PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT,

2025 VS. 2030 (USD MILLION)      59

FIGURE 18            PATIENT REGISTRY SOFTWARE MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      60

FIGURE 19            PATIENT REGISTRY SOFTWARE MARKET: GEOGRAPHICAL SNAPSHOT       61

FIGURE 20            GROWING DEMAND FOR REAL-WORLD EVIDENCE, INTEROPERABILITY, AND REGULATORY COMPLIANCE TO DRIVE MARKET GROWTH       62

FIGURE 21            SITE-BASED/CLINICAL DATA (PROVIDER-RECORDED) REGISTRIES IN NORTH AMERICA TO ACCOUNT FOR LARGEST MARKET SHARE IN 2025   63

FIGURE 22            CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       64

FIGURE 23            GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD       65

FIGURE 24            PATIENT REGISTRY SOFTWARE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 66

FIGURE 25            TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES           75

FIGURE 26            PATIENT REGISTRY SOFTWARE MARKET: ECOSYSTEM ANALYSIS  78

FIGURE 27            PATIENT REGISTRY SOFTWARE MARKET: VALUE CHAIN ANALYSIS               80

FIGURE 28            PATIENT REGISTRY SOFTWARE MARKET: PORTER’S FIVE FORCES ANALYSIS           95

FIGURE 29            GLOBAL PATENT PUBLICATION TRENDS IN PATIENT REGISTRY SOFTWARE,

2015–2025              97

FIGURE 30            JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “PATIENT REGISTRY SOFTWARE” PATENTS (JANUARY 2015–JUNE 2025)           97

FIGURE 31            MAJOR PATENTS IN PATIENT REGISTRY SOFTWARE MARKET

(JANUARY 2015–JUNE 2025)           98

FIGURE 32            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS            100

FIGURE 33            KEY BUYING CRITERIA FOR TOP THREE END USERS   101

FIGURE 35            MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING PATIENT REGISTRY SOFTWARE ACROSS INDUSTRIES       109

FIGURE 36            IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS   111

FIGURE 37            NORTH AMERICA: PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT               167

FIGURE 38            EUROPE: PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT       184

FIGURE 39            ASIA PACIFIC: PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT       217

FIGURE 40            REVENUE ANALYSIS OF KEY PLAYERS IN PATIENT REGISTRY SOFTWARE MARKET, 2020–2024 (USD MILLION)            284

FIGURE 41            MARKET SHARE ANALYSIS OF KEY PLAYERS IN PATIENT

REGISTRY SOFTWARE MARKET (2024)    285

FIGURE 42            PATIENT REGISTRY SOFTWARE MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       288

FIGURE 43            PATIENT REGISTRY SOFTWARE MARKET: COMPANY FOOTPRINT 289

FIGURE 44            PATIENT REGISTRY SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 297

FIGURE 45            EV/EBITDA OF KEY VENDORS   299

FIGURE 46            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS      299

FIGURE 47            PATIENT REGISTRY SOFTWARE MARKET: BRAND/SOFTWARE

COMPARATIVE ANALYSIS            300

FIGURE 48            IBM: COMPANY SNAPSHOT (2024)            305

FIGURE 49            IQVIA HOLDINGS INC.: COMPANY SNAPSHOT (2024)    309

FIGURE 50            HEALTH CATALYST, INC.: COMPANY SNAPSHOT (2024)             313

FIGURE 51            ORACLE: COMPANY SNAPSHOT (2024)   318

FIGURE 52            UNITEDHEALTH GROUP: COMPANY SNAPSHOT (2024)    322

FIGURE 53            CONDUENT INCORPORATED: COMPANY SNAPSHOT (2024)             325

FIGURE 54            ELEKTA: COMPANY SNAPSHOT (2024)    329

FIGURE 55            NEC CORPORATION (NEC SOFTWARE SOLUTIONS UK LIMITED): COMPANY SNAPSHOT             332

FIGURE 56            DASSAULT SYSTÈMES (MEDIDATA): COMPANY SNAPSHOT (2024)             335

FIGURE 57            VERADIGM LLC: COMPANY SNAPSHOT (2022)                 352

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧